Phase II trial of α‐tocopherol (vitamin E) in the treatment of primary systemic amyloidosis

Morie Gertz, Robert A. Kyle

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Primary systemic amyloidosis (AL) is a rare disorder characterized by deposition of a monoclonal immunoglobulin light chain or fragment thereof, resulting in dysfunction of the heart, kidney, liver, or nerves. Despite the use of melphalan, prednisone, colchicine, and dimethyl sulfoxide (DMSO), no improvement in median survival has been reported in prospective randomized studies. We undertook a study of α‐tocopherol acetate (vitamin E) in the treatment of 16 patients with AL because of its reported benefits in animal models of senile and secondary amyloidosis as well as reported benefit in the treatment of secondary amyloidosis in humans. None of the patients showed any objective regression of their disease. The median survival of the entire group was 19.4 months. This survival is not superior to that reported with other agents used in this disease. We conclude that α‐tocopherol is not a valuable agent in the treatment of AL.

Original languageEnglish (US)
Pages (from-to)55-58
Number of pages4
JournalAmerican Journal of Hematology
Volume34
Issue number1
DOIs
StatePublished - Jan 1 1990

Fingerprint

Tocopherols
Amyloidosis
Vitamin E
Survival
Immunoglobulin Light Chains
Immunoglobulin Fragments
Melphalan
Colchicine
alpha-Tocopherol
Therapeutics
Prednisone
Dimethyl Sulfoxide
Animal Models
Prospective Studies
Kidney
Primary amyloidosis
Liver

Keywords

  • cardiomyopathy
  • nephrotic syndrome
  • primary amyloidosis

ASJC Scopus subject areas

  • Hematology

Cite this

Phase II trial of α‐tocopherol (vitamin E) in the treatment of primary systemic amyloidosis. / Gertz, Morie; Kyle, Robert A.

In: American Journal of Hematology, Vol. 34, No. 1, 01.01.1990, p. 55-58.

Research output: Contribution to journalArticle

@article{e9904afe3faa45cfbc7b44a750513d02,
title = "Phase II trial of α‐tocopherol (vitamin E) in the treatment of primary systemic amyloidosis",
abstract = "Primary systemic amyloidosis (AL) is a rare disorder characterized by deposition of a monoclonal immunoglobulin light chain or fragment thereof, resulting in dysfunction of the heart, kidney, liver, or nerves. Despite the use of melphalan, prednisone, colchicine, and dimethyl sulfoxide (DMSO), no improvement in median survival has been reported in prospective randomized studies. We undertook a study of α‐tocopherol acetate (vitamin E) in the treatment of 16 patients with AL because of its reported benefits in animal models of senile and secondary amyloidosis as well as reported benefit in the treatment of secondary amyloidosis in humans. None of the patients showed any objective regression of their disease. The median survival of the entire group was 19.4 months. This survival is not superior to that reported with other agents used in this disease. We conclude that α‐tocopherol is not a valuable agent in the treatment of AL.",
keywords = "cardiomyopathy, nephrotic syndrome, primary amyloidosis",
author = "Morie Gertz and Kyle, {Robert A.}",
year = "1990",
month = "1",
day = "1",
doi = "10.1002/ajh.2830340112",
language = "English (US)",
volume = "34",
pages = "55--58",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Phase II trial of α‐tocopherol (vitamin E) in the treatment of primary systemic amyloidosis

AU - Gertz, Morie

AU - Kyle, Robert A.

PY - 1990/1/1

Y1 - 1990/1/1

N2 - Primary systemic amyloidosis (AL) is a rare disorder characterized by deposition of a monoclonal immunoglobulin light chain or fragment thereof, resulting in dysfunction of the heart, kidney, liver, or nerves. Despite the use of melphalan, prednisone, colchicine, and dimethyl sulfoxide (DMSO), no improvement in median survival has been reported in prospective randomized studies. We undertook a study of α‐tocopherol acetate (vitamin E) in the treatment of 16 patients with AL because of its reported benefits in animal models of senile and secondary amyloidosis as well as reported benefit in the treatment of secondary amyloidosis in humans. None of the patients showed any objective regression of their disease. The median survival of the entire group was 19.4 months. This survival is not superior to that reported with other agents used in this disease. We conclude that α‐tocopherol is not a valuable agent in the treatment of AL.

AB - Primary systemic amyloidosis (AL) is a rare disorder characterized by deposition of a monoclonal immunoglobulin light chain or fragment thereof, resulting in dysfunction of the heart, kidney, liver, or nerves. Despite the use of melphalan, prednisone, colchicine, and dimethyl sulfoxide (DMSO), no improvement in median survival has been reported in prospective randomized studies. We undertook a study of α‐tocopherol acetate (vitamin E) in the treatment of 16 patients with AL because of its reported benefits in animal models of senile and secondary amyloidosis as well as reported benefit in the treatment of secondary amyloidosis in humans. None of the patients showed any objective regression of their disease. The median survival of the entire group was 19.4 months. This survival is not superior to that reported with other agents used in this disease. We conclude that α‐tocopherol is not a valuable agent in the treatment of AL.

KW - cardiomyopathy

KW - nephrotic syndrome

KW - primary amyloidosis

UR - http://www.scopus.com/inward/record.url?scp=0025303873&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025303873&partnerID=8YFLogxK

U2 - 10.1002/ajh.2830340112

DO - 10.1002/ajh.2830340112

M3 - Article

C2 - 2327405

AN - SCOPUS:0025303873

VL - 34

SP - 55

EP - 58

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 1

ER -